共 50 条
- [41] Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trialsDIABETOLOGY & METABOLIC SYNDROME, 2025, 17 (01):Mousavi, AsmaShojaei, ShayanSoleimani, HamidrezaSemirani-Nezhad, DavoodEbrahimi, PouyaZafari, AliEbrahimi, RasoulRoozbehi, KhatereHarrison, AnilSyed, Mushabbar A.Kuno, ToshikiAskari, Mani KhorsandAlmandoz, Jaime P.Jun, JohnHosseini, Kaveh
- [42] Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analysesRMD OPEN, 2019, 5 (01):Choy, ErnestFreemantle, NickProudfoot, ClareChen, Chieh-IPollissard, LaurenceKuznik, AndreasVan Hoogstraten, HubertMangan, ErinCarita, PauloThi-Minh-Thao Huynh
- [43] Nora: Real World Evidence in Renal Cell Carcinoma; A National, Prospective, Non-Interventional Study in Patients with Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior TherapyONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 75 - 75Mueeller-Huesmann, HaraldBedke, JensGruenwald, ViktorBelz, HanjoBoegetnann, MartinHerber, Martinvon der Heyde, EyckIvanyi, PhilippKretzschmar, AlbrechtSchostak, MartinSchultze-Seemann, WolfgangGrimm, Marc-Oliver
- [44] Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitorsFRONTIERS IN ONCOLOGY, 2023, 13Hsu, Ping-ChihHuang, Chun-YaoLin, Yu-ChingLee, Suey-HaurChiu, Li-ChungWu, Chiao-EnKuo, Scott Chih-HsiJu, Jia-ShiuanHuang, Allen Chung-ChengKo, Ho-WenWang, Chin-ChouYang, Cheng-Ta
- [45] A Single Arm Clinical Trial to Assess the Efficacy and Safety of Panitumumab (Vectibix®) in combination with FOLFOX4 Chemotherapy as 1st line treatment in Subjects with Metastatic Gastric or Gastroesophageal Junction adenocarcinoma (VEGA trial). A multicenter Phase II SICOG trial 0802ANNALS OF ONCOLOGY, 2015, 26 : 92 - 93Casaretti, R.Comella, P.Carlomagno, C.Maiorino, L.Greco, E.Russo, A.Sanna, G.Barzelloni, M. L.Massidda, B.Formica, V.Serci, C.Defraia, S.Palmieri, G.Ionta, M. T.
- [46] Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel with or without bevacizumab as second-line therapy or beyond for patients with metastatic non-small-cell lung cancer.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Zhang, FanLi, TaoZhang, YuziCai, ShangliZhao, LeiJiao, Shun ChangHu, Yi
- [47] Safety and efficacy of combination therapy using programmed cell death protein-1/programmed cell death ligand-1 inhibitors and radiotherapy in patients with non-small-cell lung cancer: A systematic review and meta-analysisCANCER MEDICINE, 2021, 10 (04): : 1222 - 1239Geng, YichaoZhang, QiuningFeng, ShuangwuLi, ChengchengWang, LinaZhao, XueshanYang, ZhenLi, ZhengLuo, HongtaoLiu, RuifengLu, BingWang, Xiaohu
- [48] Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Zhao, MinminShen, YangZhou, YingChen, BingweiWu, XinMiao, PengchengJiang, ZhiZhu, TaoXu, XizhongZhang, BeiYuan, DonglanZhang, YangSun, WeiHe, AiqinZhao, MinHou, WenjieShao, ZhuyanJia, MeiqunZhu, YanlingChen, Jun
- [49] Comparison of efficacy and safety of high-dose chemotherapy as 1st salvage vs. 2nd or subsequent salvage therapy in relapsed or refractory germ cell tumor patients - a retrospective single-center analysisONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 73 - 73Engel, N. W.Oing, C.Bokemeyer, C.Seidel, C.
- [50] Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-AsiaLUNG CANCER, 2024, 197Kato, YukiUdagawa, HibikiMatsumoto, ShingoIzumi, HirokiOhe, YuichiroKato, TerufumiNishino, KazumiMiyamoto, ShingoKawana, SachikoChikamori, KenichiShingyoji, MasatoSato, YukiTakada, YujiToyozawa, RyoAzuma, KoichiTanaka, YuSakai, TetsuyaShibata, YujiSugiyama, EriNosaki, KanameZenke, YoshitakaUmemura, ShigekiYoh, KiyotakaSeike, MasahiroGoto, Koichi